GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.

Type
Public
HQ
Rockville, US
Founded
2003
Size (employees)
42 (est)
GlycoMimetics was founded in 2003 and is headquartered in Rockville, US
Report incorrect company information

Key People/Management at GlycoMimetics

Brian Hahn

Brian Hahn

Chief Financial Officer
John Baldwin

John Baldwin

Director
Michael Henos

Michael Henos

Director
Franklin H. Top

Franklin H. Top

Director
William Gust

William Gust

Director
M. James Barrett

M. James Barrett

Chairman of the Board of Directors

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville
Rockville, US (HQ)
9708 Medical Center Dr
Show all (1)
Report incorrect company information

GlycoMimetics Financials and Metrics

GlycoMimetics Financials

GlycoMimetics's revenue was reported to be $18.50 k in FY, 2016 which is a 99.9% decrease from the previous period.
USD

EBIT (FY, 2017)

(33.9 m)

Market capitalization (23-Apr-2018)

375.7 m

Cash (31-Dec-2017)

123.9 m
GlycoMimetics's current market capitalization is $375.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

15 m20.1 m18.5 k

Revenue growth, %

34%(100%)

EBIT

(11.1 m)(12.8 m)

EBIT margin, %

(74%)(64%)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)(24 m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

55.2 m46.8 m40 m123.9 m

Accounts Receivable

13.6 m

Inventories

916.2 k441.8 k478.5 k

Current Assets

56.1 m47.2 m40.5 m127.2 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

57 m66.2 m61.4 m46.6 m40.2 m53.8 m38.8 m53.1 m45.3 m34.6 m119.1 m112.9 m

Accounts Receivable

20 m

Inventories

1 m

Current Assets

57.7 m67.1 m61.9 m47.3 m60.8 m54.5 m39.5 m54.5 m46.5 m35.3 m119.7 m113.9 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(11.1 m)(12.8 m)(31.8 m)(33.3 m)

Depreciation and Amortization

158.7 k191.5 k190.5 k263.5 k

Inventories

1.7 m474.4 k(36.7 k)

Accounts Payable

(270.9 k)(309.8 k)1 m1.1 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.1 m)2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)(16.1 m)(24 m)

Depreciation and Amortization

34.6 k73.5 k114.3 k44.2 k90.5 k142.4 k47.2 k93.9 k139.7 k54.3 k123.9 k

Inventories

1 m

Accounts Payable

652.1 k(672.7 k)(561.2 k)299.5 k222.5 k(240.9 k)1 m816.9 k682.5 k(1.1 m)(990.1 k)1.6 m
USDY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

GlycoMimetics News and Updates

New Detailed Study on Anemia Drugs Market by Leading Key Players: GlycoMimetics, Mast Therapeutics, Fibrogen

Anemia Drugs Market Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information